JP2826134B2 - Patch - Google Patents

Description

Description: TECHNICAL FIELD The present invention relates to a patch having an excellent analgesic and anti-inflammatory effect without a decrease in the medicinal effect even when stored for a long period of time.

[Conventional technology]

Many inflammatory pain disorders, such as arthritis, myositis and tendonitis, occur locally and at sites relatively close to the body surface. Therefore, if non-steroidal anti-inflammatory drugs can be absorbed percutaneously and a higher drug distribution can be obtained in the inflamed area than in the blood, high local efficacy and gastrointestinal tract disorders often associated with systemic application It is expected to reduce side effects.

At present, the usefulness of ointments containing nonsteroidal anti-inflammatory drugs in the treatment of orthopedic diseases is evaluated as being more safe than oral preparations or being easily administered to limb joints. However, ointments do not sufficiently meet the objectives in terms of the uniformity of the dose, the stability of the preparation after administration, the sustained efficacy, and the like due to the properties of the ointment.

Patches are another formulation that is expected to have the same effect. This is a form commonly called a compress, in which an ointment is applied to one side of the cloth, which is superior to ointment in terms of formulation stability, uniformity of dosage, and sustained efficacy. It is a preparation.

However, conventional patches, when the storage period until the actual use is long, the medicinal effect often drops from the initial state, and even during actual use, There has been a problem that the medicinal effect is significantly reduced when the use time is prolonged. Particularly, in recent years, since synthetic fibers such as polyethylene terephthalate fibers have been widely used as a base fabric for patches, the above-mentioned problems have often occurred.

[Problems to be solved by the invention]

Accordingly, an object of the present invention is to obtain a patch having an excellent analgesic and anti-inflammatory effect without a decrease in the medicinal effect even when stored for a long period of time. The present inventors have conducted intensive studies on what composition and what requirements should be set as a patch for such a purpose, and have reached the present invention.

[Means for solving the problem]

In the present invention, the ethylene content is 25 to 70 mol%, and the degree of saponification is
95% or more of saponified ethylene-vinyl acetate copolymer (A
Polymer) and a crystalline thermoplastic polymer (B polymer) having a melting point of 150 ° C. or more and having fiber forming properties.
10% of composite fibers, where polymer accounts for more than 60% of fiber circumference
An excellent analgesic and anti-inflammatory effect without a decrease in the medicinal effect over time, characterized in that vegetable oils obtained by dissolving and dispersing a non-steroidal transdermal analgesic and anti-inflammatory agent are applied to the fiber assembly surface layer containing the above. Is a patch having the formula:

As the non-steroidal percutaneous analgesic and anti-inflammatory drug used in the present invention, basically, any drug which is currently effective as a non-steroidal anti-inflammatory analgesic can be used. Especially among them, ketoprofen, indomethacin, flurbiprofen, methyl salicylate,
Diclofenac, ibuprofenmenthol and the like are effective drugs.

For example, if the drug is described in detail in a few ways, flurbiprofen has the action mechanism of inhibiting prostaglandine biosynthesis, inhibiting vascular permeability increase, inhibiting leukocyte migration, inhibiting protein denaturation. Action,
It is thought that cell membrane stabilizing action and bradykinin release inhibitory action are involved. These actions work in cooperation with local inflammation to exert strong anti-inflammatory and analgesic actions. Conceivable. Transdermal non-steroidal anti-inflammatory using flurbiprofen; analgesic was approved on March 29, 1988, and three types of products are now being marketed: Adfeed, Zeporus and Stayban. I'm wearing

Indomethacin is also a nonsteroidal anti-inflammatory and analgesic, and is currently recognized as the most effective substance.
Similarly, the mechanism of action of indomethacin is similar to that of inhibiting prostaglandine biosynthesis, inhibiting vascular permeability, inhibiting leukocyte migration, inhibiting protein denaturation, stabilizing cell membranes, and inhibiting bradykinin.
in) It is considered that release inhibition and the like are involved, and it is considered that these actions act cooperatively at the local site of inflammation to exert a strong anti-inflammatory and analgesic action. Since the production and approval of gels of indomethacin in 1980, they have been used as oral preparations, injections and suppositories, and have come into the spotlight. Indomethacin was approved on March 29, 1988, and three types of products, "Catrep", "Idomesin Kowapap", and "Insidepap" have been marketed.

Another typical drug is ketoprofen, which is thought to exert the same mechanism of action as indomethacin, and has been widely used. Ketoprofen was approved on March 29, 1988 and is currently "Morous"
Three kinds of products, "Mirtax" and "Kefina", have been marketed.

One of the above non-steroidal transdermal analgesics and anti-inflammatory agents may be used alone, or two or more may be used in combination. Usually, one kind of drug exerts a sufficient drug effect.

Generally, the patch has a structure in which a mixture of a drug and a base is applied to a base cloth made of a fiber aggregate and a release paper is stuck thereon, but in recent years, synthetic fibers such as polyethylene terephthalate have been used as the base cloth. Since it has been widely used, it has been observed that a medicinal effect is often reduced under the condition that a patch is stored for a long period of time.

The present inventors have conducted intensive studies on the cause, and as a result,
It has been found that there is a major factor in the base material applied with the drug. That is, it was found that the vegetable oils used for dissolving the drug were exhausted into the fibers while the patch was stored, and the effective drug amount gradually decreased. The present inventors have clarified what kind of material should be used as a fiber material in order to suppress such a phenomenon that the drug effect becomes negative.

As the vegetable oils described here, a fiber is used together with a base material for dissolving the drug and bringing it into close contact with other skin, for example, gelatin in which titanium oxide is mixed, and a skin infiltrant such as glycerin. A medium to be applied to the surface of the base fabric, specifically, Avies oil, Amiris oil, Angelica oil, Ambrett seed oil, Ylang Ylang oil, Elemi oil, Oak Moss oil, Oyutiya oil, Origanum oil, Oris oil, Cassie oil, cananga oil, camomill oil, kayapte oil, columus oil, galvanum oil, guaiac oil, grapefruit oil, Costas oil, bitter oil,
Citronella oil, Jasmine oil, grape brain oil, sweet orange oil, stylax oil, spearmint oil, sedarwood oil, geranium oil, dabana oil, tansy oil, turpentine oil, chiyverose flower essential oil, neroli oil, pine oil, pachiyuri oil, hatsuka oil , Vanilla oil, balsam copaiba oil,
Balsam true oil, balsam peru oil, palmarosa oil, hillip oil, bitter almond oil, bitter orange oil, hiba oil, vetiver oil, peppermint oil, penny royal oil, perilla oil, percamotet oil, benzoin oil,
Natural vegetable oils such as boa de rose oil, fragrance oil, mandarin oil, eucalyptus oil, lavandin oil, lavender oil, lemon oil, lemongrass oil, rose oil, rosemary oil and the main of these natural vegetable oils Synthetic compounds that mimic the components, i.e., terpene-based hydrocarbons such as α-pinene, β-pinene, camphene, limonene, myrcene, β-calyolefylene, linalool, geraniol, nerol, citronellol, lavandulol, myrcenol, α-terpineol, Z- Menthol, polneol, nobor,
Terpene alcohols such as isobornylcyclohexanol, fuarnesol, nerolidol, santalol, cedrol, pakiuri alcohol, benzyl alcohol, phenethyl alcohol, γ-phenylpropyl alcohol, cinnamic alcohol, anth alcohol, d-α-
Alcohols such as dimethylphenylethyl alcohol, α-phenylethanol, β-phenylethyldimethylcarbinol, phenoxyethanol, and patch, diphenylether isosafluoroeugenol, p-methylanisole, anethole, eugenol, isoeugenol,
Phenols and derivatives thereof such as methyl eugenol, methyl isoeugenol, benzyl isoeugenol, safrole, isosafurol, methyl-β-naphthyl ether, ethyl-β-naphthyl ether, heptanal,
Aliphatic aldehydes such as octanal, nonanal, decanal, undecanal, dodecanal, 2-methylundecanal, tridecanal, tetradecanal, hexadecanal, trans-2-hexanal, 2,6-nonadienal, citral, citronellal, and hydroxy Terpene aldehydes such as citronellal, perilaldehyde, citronellyloxyacetaldehyde, lillal, sinensal, benzaldehyde, phenylacetaldehyde, 3-phenylpropionaldehyde;
Cinnamaldehyde, α-amyl cinnamaldehyde,
α-hexylcinnamaldehyde, anisaldehyde,
Aromatic aldehydes such as cuminaldehyde, piperonal, cyclamenaldehyde, pt-butyl-α-methyldihydrocinnamaldehyde, vanillin, boubonal, citral methyl acetal, citral diethyl acetal, hydroxycitronellal dimethyl acetal, phenylacetaldehyde dimethyl acetal Isoacetals, 2-heptanone, 3-octanone, 2-
Aliphatic ketones such as octanone and 2-undecanone, carboxylic acids, mentones, terpene ketones such as pulegone, p-methylacetophenone, p-methoxyacetophenone, benzophenone, benzylideneacetone, anisylacetone, p-hydroxybenzylacetone, 2 -Aromatic ketones such as acetonaphthone, α-, β-, γ-ionone, α-
n, β-n, γ-n methylionone, α-, β-, γ-
Isomethylionone, α-, β-, γ-iron, α-,
β-Damasenone, α-, β-, γ-damascon, theaspirane, theaspiron, ezran, rosefuran, nootkatone, α-vetibon, cis-diasmon, dihydrodiasmon, methyl diasmonate, methyl dihydrodiasmonate, jasmine lactone Alicyclic ketones such as maltol, cycloten, and furaneol, alicyclic ethers, alicyclic lactones, muscone, civetone, cyclopentadecanone, cyclopentadecanolide, ambretride,
Cyclohexadecanolide, ethylene brasilate, 12-
Macrocyclic ketones such as oxahexadecanolide, 11-oxahexadecanolide, and 10-oxahexadecanolide, lactones, musk xylene, musk ketone, musk ambled, mosquen, celestride, fantrid, tonalide, borakilide, etc. , Rose oxide, oxide ketone, linalool oxide, 1,8-cineole, reduced ethers such as bicyclodihydrohomophanesyl oxide, indole, skatole, 6-methylquinoline, 7-methylquinoline, 6-isopropylquinoline, 2- Methyltetrahydroquinoline, 6-methyltetrahydroquinoline, 2-isobutylthiazole, 2-
Furylmethanethiol, 2-methylpyrazine, 2,5-dimethylpyrazine, 2,3,5-trimethylpyrazine, and other complex-reduced compounds, geranyl formate, benzyl formate, ethyl acetate,
Esters of aliphatic acids such as geranyl acetate, methyl benzoate,
It is a synthetic vegetable oil comprising a mixture of isolamil benzoate, ethyl anthate, methyl salicylate, esters of aromatic acids such as methyl cinnamate, and the like.

Hatsuka oil used as a representative example will be described as an example. Various polymers were made into a film shape, and menthol, which is a main component in atsuka oil, was tested for permeability. As a test method, various plastic films
Menthol 1 into a 5 x 10cm ² sachet of 15 ~ 25μ thickness
g and sealed with an impulse sealer. 250 for each sachet
It was placed in a deodorized glass bottle of CC, and the time until the odor was felt was measured. As a result, polyethylene terephthalate, polycarbonate, polyethylene, etc. begin to smell in a glass bottle within one week, whereas the saponified film of ethylene-vinyl acetate copolymer does not smell even after two weeks or more. It can be seen that there is excellent barrier property without being felt. It can be said that the present invention has been found by utilizing the oil resistance properties of the saponified ethylene-vinyl acetate copolymer.

That is, it is an important point of the present invention that a saponified polymer of an ethylene-vinyl acetate copolymer (hereinafter abbreviated as A polymer) is used as a fiber material for a patch base fabric. It is of course possible to produce fibers of the A polymer alone, but the fiberization process is slightly inferior, the dimensional stability of the fibers, and the heat resistance when wet is slightly inferior. The composite fiber was spun with a crystalline thermoplastic polymer (hereinafter abbreviated as B polymer) having a good melting point and a melting point of 150 ° C. or higher, and a composite fiber was used. At this time, if the A polymer occupies about 60% or more of the fiber circumference, the effect of oil resistance on the vegetable oils is exhibited,
It has been found that it is sufficiently effective to maintain the desired duration of the drug effect.

As the saponified ethylene-vinyl acetate copolymer as the component A, those having a high degree of saponification of 95% or more and an ethylene content of 25 to 70 mol%, that is, a vinyl alcohol component of 30 to 70 mol% The one with 75 mol% is optimal. If the content of the vinyl alcohol component in the A polymer is low, the oil resistance to vegetable oils is naturally lowered due to the reduction of hydroxyl groups (OH), and the desired good durability of the medicinal effect cannot be obtained. Not preferred. When the content of the vinyl alcohol component is too large, the melt-molding property is reduced, and when the fiber is formed into a fiber after being composite-spun with the B component, the spinnability becomes poor, and the single yarn breakage and the breakage increase. Absent. As an example, when polyester is used as the component B, the heat resistance at a spinning temperature of 250 ° C. or higher becomes insufficient, which is not suitable. Therefore, those having a high saponification degree and a vinyl alcohol component content of 30 to 75 mol% are suitable for obtaining the desired fiber.

The A polymer is produced by saponifying the copolymer of ethylene and vinyl acetate with caustic soda, and the saponification degree at this time is preferably 95% or more. When the degree of saponification is low, not only the crystallinity of the polymer is lowered and the fiber properties such as strength are lowered, but also the polymer A is easily softened, causing troubles in the processing step and the obtained fiber structure. The feeling of the object also deteriorates, which is not preferable. Further, the oil resistance is significantly reduced, so that the intended effect of the present invention is reduced.

As the B polymer having a melting point of 150 ° C. or higher in the present invention,
Any polymer having a melting point of 150 ° C. or higher and a good fiber-forming property may be used. Preferably, a polyester mainly composed of polyethylene terephthalate, polybutylene terephthalate or polyhexamethylene terephthalate, or a polyamide mainly composed of nylon 6, nylon 66 or nylon 12 is preferred.

Examples of the polyester include terephthalic acid, isophthalic acid, naphthalene 2,6-dicarboxylic acid, phthalic acid, α, β- (4-carboxyphenoxy) ethane,
Aromatic dicarboxylic acids such as 4-dicarboxydiphenyl, pentasodium sulfoisophthalic acid or aliphatic dicarboxylic acids such as adipic acid and sebacic acid or esters thereof, and ethylene glycol, diethylene glycol, 1,4 butanediol, 1 A fiber-forming polyester synthesized from a diol compound such as 1,6 hexanediol, neopentyl glycol, cyclohexane 1,4-dimethanol, polyethylene glycol, or polytetramethylene glycol. Polyesters that are terephthalate units or polybutylene terephthalate units or polyhexamethylene terephthalate units are preferred. The polyester may contain a small amount of additives, fluorescent brighteners, stabilizers, ultraviolet absorbers and the like.

As polyamide, nylon 6, nylon 66,
It is a polyamide containing nylon 12 as a main component, and may be a polyamide containing a small amount of a third component. These may contain small amounts of additives, optical brighteners, stabilizers and the like.

A specific example of a cross-sectional shape as a composite form of the composite fiber of the present invention will be described with reference to the drawings. A complete core-sheath composite fiber as shown in FIG. 1 and a core-sheath having a core component having an irregular shape as shown in FIGS. 4, a multi-core composite fiber as shown in FIG. 4, an eccentric core-sheath composite fiber as shown in FIG. 6, a modified cross-section core-sheath composite fiber as shown in FIGS. Fibers, multi-layer laminated conjugate fibers as shown in FIG. 9, modified multi-layer composite fibers as shown in FIG. 11, random composite fibers as shown in FIGS. 12 and 13, and the like are also included. The component (a) in FIGS. 1 to 13 is a saponified ethylene vinyl acetate copolymer, and (b)
The component is a thermoplastic polymer having a melting point of 150 ° C. or higher. It is desirable that the component polymer occupies about 60% or more of the fiber cross-sectional circumference. If it is less than 60%, as described above, it is difficult to obtain characteristics of a fiber base fabric for a patch having a good and durable medicinal effect for the purpose of the present invention. A
The composite ratio of the component and the component B is preferably in the range of 80:20 to 20: 80% by weight. If the content of the component A is less than 20% by weight, the oil resistance to the good vegetable oils aimed at by the present invention becomes insufficient, which is not preferable. On the other hand, if it exceeds 80% by weight, the processability such as spinnability and stretchability is reduced, and A
It is not preferable because the rating is lowered.

Next, a brief description will be given of a method for producing fibers used in the base fabric for patches of the present invention. FIG. 14 schematically shows a spinning apparatus according to the present invention.

One of the two melt extruders (1) has a resin (A), and the other (2) has a resin (B) which has better spinnability than (A).
Is filled. The polymer streams melted and extruded by the extruder are each precisely metered by a gear pump and sent to a spinning head. The two types of polymer streams are combined by a packing fitting provided on a head, and then discharged from a spinneret to be converted into fibers.

The composite form of the resins (A) and (B) takes into account the performance of medicinal properties, the performance such as durability, and the processability such as spinnability and stretchability. It was found that any form that included 60% of the above was acceptable.

When kneading the resins (A) and (B) to some extent as shown in FIGS. 12 and 13, a static mixer is used.

The spinning speed may be either 3000 m / min or less, as in general fibers, or high speed spinning at 3000 to 5000 m / min. The polymer A alone lacks spinnability, but by combining it with PET, PBT, nylon, or the like, considerable high-speed spinning can be performed without any problem. Depending on the resin to be compounded and the form of the compound, the two resins may peel off during stretching, and in that case, high-speed spinning would be effective. Otherwise, it is also possible to obtain a high-strength yarn by spinning at a normal spinning speed and securely stretching.

The obtained fibers are then formed in the form of various fiber aggregates required according to the purpose. Although a fiber aggregate may be formed using 100% of the composite fiber, the effect of the present invention can be obtained by mixing other fibers. However, if the mixing ratio of the conjugate fiber is too small, the effect obtained is naturally reduced, and it is preferable to maintain 10% or more.

The fiber aggregate may be in any form such as a nonwoven fabric, a knitted fabric or a woven fabric, but the nonwoven fabric is optimal in terms of cost.

 Next, the present invention will be described specifically with reference to examples.

[Example 1] As a polymer A, the degree of saponification was 99% and the ethylene content was 44.
A mol% of a saponified ethylene-vinyl acetate copolymer was used, and as the B polymer, [η] 0.60 (intrinsic viscosity measured at 30 ° C. with an equivalent solution of phenol and tetrachloroethane)
Each of the polyethylene terephthalates was melt-extruded with a separate extruder, weighed with a gear pump so that the weight ratio of the A polymer and the B polymer was 50:50, and then supplied to the spinning pack. Is the sheath component, and the core-sheath composite shape is such that the B polymer is the core component.
Discharge from the die heated at 5 ℃, winding speed 1000m / min
The spun yarn was collected at. Thereafter, the obtained spun yarn is stretched at a water bath temperature of 75 ° C., and then shrinks at a water bath temperature of 90 ° C. by 5%.
% To obtain a drawn yarn. Next, mechanical crimping is performed by a conventional method, then a general oil agent is applied to a concentration of 0.1 wt%, relaxed and heat-treated at 100 ° C for 15 minutes, and then cut into a length of 51 mm to obtain a single denier 2.0 raw cotton. And

Then, after blending 20% of 2 denier × 51 mm of binder fiber (Softit N-720 manufactured by Kuraray Co., Ltd.) having polyethylene terephthalate as a core component and a copolyester as a sheath component, a web having a basis weight of 100 g / m ² was prepared. Thereafter, a hot air treatment was performed to prepare a nonwoven fabric, which was used as a base fabric for patches. The processability from spinning to preparation of the final nonwoven fabric was good and no problem.

A 5% indomethacin oil solution was applied to the surface of the nonwoven fabric together with gelatin, titanium oxide, and other bases of glycerin to prepare a patch under such conditions that 70 mg of indomethacin was applied to 1 g of the nonwoven fabric. A standing test was performed with the release paper adhered to the surface. Thereafter, the concentration of the applied indomethacin was estimated over time from the calibration curve by measuring the absorption intensity at a wavelength of 319 nm of the ultraviolet absorption spectrum, and the residual amount was measured. The results are shown in Table 1. No decrease in the amount of applied drug with time was observed. The effect as a patch was also tested using 10 males and females.

[Comparative Example 1] A polyethylene terephthalate fiber was spun by an ordinary method,
It was obtained by stretching. Thereafter, a 2-denier 51 mm raw cotton was prepared by a conventional method, and 2% denier × 51 mm binder fiber 51% × 51 mm manufactured by Kuraray Co., Ltd. was mixed with the polyester raw cotton at 20%, and a wet weight of 100 g / m ² was prepared. Thereafter, a non-woven fabric was prepared by performing a hot-air treatment to obtain a base fabric for a patch. Thereafter, a drug and a base were applied under the same conditions as in Example 1, and a leaving test was carried out with a release paper stuck to the surface. The results are shown in Table 1. The decrease in the amount of applied drug over time was observed, and the exhaustion of the drug to the fiber base cloth progressed, indicating that the effective amount of the drug on the coated surface was reduced. Was estimated. In addition, in the actual use test, it was confirmed that the medicinal effect decreased with time.

[Comparative Example 2] As the A polymer, high-density polyethylene (Mitsubishi Kasei Corporation Yucalon Bird JX-10) was used, and as the B polymer, polyethylene terephthalate of [η] 0.60 was used.
Otherwise, in the same manner as in Example 1, raw cotton having a core-sheath composite shape in which the polymer A was a sheath component and the polymer B was a core component was prepared. Next, a web having a basis weight of 100 g / m ² was prepared, and then subjected to hot air treatment to prepare a nonwoven fabric, which was used as a base fabric for patches. Thereafter, a leave test was carried out under the same conditions as in Example 1 with the drug and the base applied and a release paper attached to the surface. The results are shown in Table 1. The decrease in the amount of applied drug over time was observed, and the exhaustion of the drug to the fiber base cloth progressed, indicating that the effective amount of the drug on the coated surface was reduced. Was estimated. In addition, in the actual use test, it was confirmed that the medicinal effect decreased with time.

[Examples 2 and 3] Example 2 was performed in the same manner as in Example 1, except that the ethylene content of the A polymer was 32 mol%, and that of Example 3 was that the ethylene content of the A polymer was 48 mol%. Carried out. No decrease in the amount of applied drug over time was observed in any case. As for the effect as a patch, the medicinal effect was good as a result of the actual use test.

[Examples 4 and 5] In Example 3, polybutylene terephthalate (Novedol 5008, Mitsubishi Chemical Corporation) was used as the B polymer, and in Example 4, nylon 6 (Ube Industries, Ltd. 1013) was used as the B polymer.
BK), except that BK) was used.
In all cases, no decrease in the amount of drug applied over time was observed. As for the effect as a patch, the medicinal effect was good as a result of the actual use test.

[Examples 6 to 8] The cross-sectional shape was changed and tested. Example 6 shows the eccentric core-sheath cross section shown in FIG. 6, Example 7 shows the bonded shape shown in FIG. 8, and Example 8 shows that the ratio of the A polymer to the B polymer was 30.
Pair 70 and the cross-sectional shape of the non-uniformly mixed state shown in FIG. 13 were used, and the other methods were the same as in Example 1. No decrease in the amount of applied drug over time was observed in any case. As for the effect as a patch, as a result of an actual use test, the medicinal effect was good and no problem.

[Example 9] Aside from setting the ratio of the A polymer to the B polymer to 30:70,
It carried out by the same method as Example 1. No decrease over time in the amount of applied drug was observed. As for the effect as a patch, as a result of an actual use test, the medicinal effect was good and no problem.

Example 10 The same procedure as in Example 1 was carried out except that ketoprofen was used as a drug. However, the residual amount of the applied ketoprofen was measured by measuring the wavelength of 183 nm of the ultraviolet absorption spectrum. No decrease over time in the amount of applied drug was observed. As for the effect as a patch, the medicinal effect was good as a result of the actual use test.

[Comparative Example 3] A polymer having an ethylene content of 20 mol% was used, but the fluidity during melt spinning was poor, the spinnability was poor, and the fiber could not be formed.

[Comparative Example 4] A polymer was used in the same manner as in Example 1 except that the A polymer used had an ethylene content of 80%. However, the performance with the patch was not so favorable at the same level as Comparative Example 2.

[Comparative Example 5] A polymer having a degree of saponification of 80% was used as A polymer, and the other processes were performed in the same manner as in Example 1. Adhesion troubles between single yarns occurred during the spinning and drawing steps, and a fiber structure that could be evaluated was not obtained.

Table 2 summarizes data and results of the above Examples and Comparative Examples.

(Effects of the Present Invention) As described above, the present invention provides a method for satisfying predetermined conditions by using two kinds of polymers, a saponified ethylene-vinyl acetate copolymer and a crystalline thermoplastic resin having a melting point of 150 ° C. or more, satisfying specific conditions. By applying a vegetable oil in which a non-steroidal analgesic and anti-inflammatory agent excellent in percutaneous absorbability is dissolved, it is good for long-term storage by applying composite spinning to fibers and applying the fiber assembly to the fiber aggregate. It has been found that a patch with a long lasting medicinal effect is maintained.

BRIEF DESCRIPTION OF THE DRAWINGS FIGS. 1 to 13 show examples of the composite shape of the fiber of the present invention.
FIG. 14 shows an example of a spinning apparatus for obtaining the fiber of the present invention.

────────────────────────────────────────────────── ─── Continuation of the front page (56) References JP-A-2-240014 (JP, A) JP-A-1-299214 (JP, A) JP-A-1-40420 (JP, A) JP-A-62-162 26217 (JP, A) (58) Field surveyed (Int. Cl. ⁶ , DB name) A61K 9/70

Claims (2)

(57) [Claims] An ethylene content of 25 to 70 mol% and a saponification degree of 95.
% Of a saponified ethylene-vinyl acetate copolymer (A polymer) and a crystalline thermoplastic polymer (B polymer) having a fiber forming property and a melting point of 150 ° C. or more, and the A polymer is 60% or more of the fiber circumference. A patch characterized in that vegetable oils in which a non-steroidal transdermal analgesic and anti-inflammatory agent is dissolved and dispersed are applied to a fiber assembly containing 10% or more of conjugated fibers. 2. The non-steroidal transdermal analgesic and anti-inflammatory agent comprises at least one selected from ketoprofen, indomethacin, flurbiprofen, methyl salicylate, diclofenac and ibuprofenmenthol. The patch according to Item.